LA
RARE icon

Lee Ainslie’s Ultragenyx Pharmaceutical RARE Stock Holding History

Lee Ainslie’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,861
Closed -$529K – 570
2021
Q3 		$529K Sell
5,861
-4,311
-42% -$390K 0.01% 435
2021
Q2 		$970K Sell
10,172
-1,001
-9% -$104K 0.01% 307
2021
Q1 		$1.27M Buy
+11,173
New +$1.52M 0.01% 209

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lee Ainslie's RARE Position: Q4 2021 in Review

Lee Ainslie sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 5,861 shares — an estimated $529K sold.

Lee Ainslie first reported a position in RARE in Q1 2021 and held it in 3 quarters. The position peaked at $1.27M in Q1 2021. 235 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

  • Lee Ainslie reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Lee Ainslie sold 5,861 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $529K.
  • Lee Ainslie first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 3 quarters.
  • Lee Ainslie's Ultragenyx Pharmaceutical position peaked at $1.27M in Q1 2021.
  • 235 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.